Market
How will uniQure's stock price react following FDA decision on AMT-130?
2
Resolution / Starting Odds
Increase by over 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by over 10% • 25%
Stock market data and financial news reports
Story
uniQure Aligns with FDA for BLA Submission and Accelerated Approval of AMT-130 in Phase I/II Huntington's Disease Studies
Dec 10, 2024, 12:18 PM
uniQure has announced that the FDA has agreed that data from its ongoing Phase I/II studies for AMT-130, a treatment for Huntington's Disease, may serve as the primary basis for a Biologics License Application (BLA) submission under the Accelerated Approval pathway. This alignment with the FDA is seen as a significant step forward for the company, as it establishes the use of natural history external control data in the review process. The FDA's flexibility in review standards for gene therapy applications is also noted, with emphasis on the importance of biomarkers like mHTT and NfL being deprioritized in this context. The announcement has generated positive sentiment among investors, drawing comparisons to previous successful approvals in the biotech sector.
View original story
Similar markets
Increase over 20% • 25%
Decrease • 25%
No change • 25%
Increase 0-20% • 25%
Biogen stock rises >5% • 25%
Biogen stock stable ±5% • 25%
Other • 25%
Biogen stock falls >5% • 25%
Increase by 10% or more • 25%
Decrease by 10% or more • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
No significant change • 25%
Underperforms biotech index • 25%
Performs in line with biotech index • 25%
Outperforms biotech index • 25%
Increase by less than 10% • 25%
Increase by more than 10% • 25%
Decrease • 25%
No significant change • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Decrease by 0-10% • 25%
Increase by 0-10% • 25%
Increase by over 10% • 25%
Decrease by over 10% • 25%
Conditional approval • 25%
No progress • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Increase by less than 10% • 25%
Increase by more than 20% • 25%
Decrease or no change • 25%
Increase by 10% to 20% • 25%
